BioCardia Files 8-K: Other Events & Financials
Ticker: BCDA · Form: 8-K · Filed: Oct 28, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, corporate-update
TL;DR
BioCardia dropped an 8-K on 10/28, check it for other events and financials.
AI Summary
BioCardia, Inc. filed an 8-K on October 28, 2024, reporting other events and financial statements. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and headquartered in Sunnyvale, California.
Why It Matters
This filing provides updates on BioCardia's corporate activities and financial status, which are important for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting other events and financial statements, not indicating any immediate significant operational or financial distress.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- October 28, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Sunnyvale, California (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for BioCardia, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 28, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 28, 2024.
What is BioCardia, Inc.'s state of incorporation?
BioCardia, Inc. is incorporated in Delaware.
What was BioCardia, Inc. formerly known as?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc., Cardo Medical, Inc., and CLICKNSETTLE COM INC.
Where are BioCardia, Inc.'s principal executive offices located?
BioCardia, Inc.'s principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085.
Filing Stats: 422 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-10-28 09:00:11
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20241028_8k.htm (8-K) — 27KB
- ex_738159.htm (EX-99.1) — 15KB
- 0001437749-24-032196.txt ( ) — 175KB
- bcda-20241028.xsd (EX-101.SCH) — 3KB
- bcda-20241028_def.xml (EX-101.DEF) — 11KB
- bcda-20241028_lab.xml (EX-101.LAB) — 15KB
- bcda-20241028_pre.xml (EX-101.PRE) — 11KB
- bcda20241028_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 28, 2024, BioCardia, Inc. (the "Company") issued a press release announcing the completion of its last protocol specified follow-up visit in CardiAMP HF, a prospective, randomized double-blinded, placebo procedure controlled, multi-center pivotal clinical trial. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated October 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: October 28, 2024